已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Janus Kinase Inhibitors and Adverse Events of Acne

医学 痤疮 不利影响 内科学 优势比 安慰剂 贾纳斯激酶 入射(几何) 随机对照试验 梅德林 皮肤病科 替代医学 病理 物理 细胞因子 光学 政治学 法学
作者
Jeremy Martinez,Cyriac Manjaly,Priya Manjaly,Sophia Ly,Guohai Zhou,John S. Barbieri,Arash Mostaghimi
出处
期刊:JAMA Dermatology [American Medical Association]
卷期号:159 (12): 1339-1339 被引量:6
标识
DOI:10.1001/jamadermatol.2023.3830
摘要

Importance Janus kinase (JAK) inhibitors are increasingly used across a range of dermatologic conditions. Adverse events of acne have been noted in some studies in clinical practice, but the scope of this outcome across JAK inhibitors has not been established. Objective To systematically analyze all published phase 2 and 3 placebo-controlled randomized clinical trials (RCTs) of JAK inhibitors for the risk of acne as an adverse effect of these medications. Data Sources Comprehensive search of Ovid MEDLINE and PubMed databases through January 31, 2023. Study Selection Inclusion criteria were phase 2 and 3 placebo-controlled RCTs of JAK inhibitors published in English with reported adverse events of acne. Data Extraction and Synthesis Two reviewers independently reviewed and extracted information from all included studies. Main Outcomes and Measures The primary outcome of interest was the incidence of acne following JAK inhibitor use. A meta-analysis was conducted using random-effects models. Results A total of 25 unique studies (10 839 unique participants; 54% male and 46% female) were included in the final analysis. The pooled odds ratio (OR) was calculated to be 3.83 (95% CI, 2.76-5.32) with increased ORs for abrocitinib (13.47 [95% CI, 3.25-55.91]), baricitinib (4.96 [95% CI, 2.52-9.78]), upadacitinib (4.79 [95% CI, 3.61-6.37]), deucravacitinib (2.64 [95% CI, 1.44-4.86]), and deuruxolitinib (3.30 [95% CI, 1.22-8.93]). Estimated ORs were higher across studies investigating the use of JAK inhibitors for the management of dermatologic compared with nondermatologic conditions (4.67 [95% CI, 3.10-7.05]) as well as for JAK1-specific inhibitors (4.69 [95% CI, 3.56-6.18]), combined JAK1 and JAK2 inhibitors (3.43 [95% CI, 2.14-5.49]), and tyrosine kinase 2 inhibitors (2.64 [95% CI, 1.44-4.86]). Conclusions and Relevance In this systematic review and meta-analysis, JAK inhibitor use was associated with an elevated odds of acne. Patients should be properly counseled on this potential adverse effect of these medications before treatment initiation. Future studies are needed to further elucidate the pathophysiology of this association.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
小王子发布了新的文献求助10
刚刚
标致一手完成签到 ,获得积分10
1秒前
华仔应助梅者如西采纳,获得10
1秒前
3秒前
梅者如西完成签到,获得积分10
6秒前
超脱闲人发布了新的文献求助10
8秒前
科研通AI2S应助fengyuke采纳,获得10
9秒前
北觅完成签到 ,获得积分10
11秒前
可爱的函函应助七草肃采纳,获得10
13秒前
卧镁铀钳完成签到 ,获得积分10
22秒前
zz完成签到 ,获得积分10
23秒前
青羽凌雪应助fengyuke采纳,获得10
23秒前
舒适怀寒完成签到 ,获得积分10
24秒前
今后应助是你刘大爷采纳,获得10
25秒前
背后的皮带完成签到 ,获得积分10
27秒前
34秒前
wang完成签到 ,获得积分10
36秒前
hh发布了新的文献求助30
38秒前
41秒前
良良丸完成签到 ,获得积分10
42秒前
思源应助彩色的金毛采纳,获得10
43秒前
wangye完成签到 ,获得积分10
46秒前
48秒前
hua完成签到,获得积分10
49秒前
科研通AI2S应助研友_8y2G0L采纳,获得10
50秒前
hh完成签到,获得积分10
51秒前
葡紫明完成签到 ,获得积分10
51秒前
赘婿应助超脱闲人采纳,获得10
51秒前
ww发布了新的文献求助10
53秒前
脑洞疼应助zxx采纳,获得10
54秒前
56秒前
57秒前
mixcom完成签到,获得积分10
58秒前
彭于晏应助韩夏菲采纳,获得10
59秒前
suzy-123完成签到,获得积分10
1分钟前
ww完成签到,获得积分10
1分钟前
1分钟前
Hellolyj完成签到 ,获得积分10
1分钟前
蓝泡泡完成签到 ,获得积分10
1分钟前
1分钟前
高分求助中
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Very-high-order BVD Schemes Using β-variable THINC Method 890
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
A new species of Coccus (Homoptera: Coccoidea) from Malawi 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3256777
求助须知:如何正确求助?哪些是违规求助? 2898945
关于积分的说明 8303121
捐赠科研通 2568188
什么是DOI,文献DOI怎么找? 1394887
科研通“疑难数据库(出版商)”最低求助积分说明 652924
邀请新用户注册赠送积分活动 630631